These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 36330949

  • 1. Andrographolide suppresses the malignancy of triple-negative breast cancer by reducing THOC1-promoted cancer stem cell characteristics.
    Chou YJ, Lin CC, Hsu YC, Syu JL, Tseng LM, Chiu JH, Lo JF, Lin CH, Fu SL.
    Biochem Pharmacol; 2022 Dec; 206():115327. PubMed ID: 36330949
    [Abstract] [Full Text] [Related]

  • 2. THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple-Negative Breast Cancer.
    Bai X, Ni J, Beretov J, Wang S, Dong X, Graham P, Li Y.
    Adv Sci (Weinh); 2021 Dec; 8(24):e2102658. PubMed ID: 34708581
    [Abstract] [Full Text] [Related]

  • 3. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A, Kaur P, Lang JE.
    BMC Cancer; 2020 Nov 10; 20(1):1076. PubMed ID: 33167919
    [Abstract] [Full Text] [Related]

  • 4. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
    De Santis F, Romero-Cordoba SL, Castagnoli L, Volpari T, Faraci S, Fucà G, Tagliabue E, De Braud F, Pupa SM, Di Nicola M.
    Cell Oncol (Dordr); 2022 Apr 10; 45(2):257-274. PubMed ID: 35357654
    [Abstract] [Full Text] [Related]

  • 5. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
    Zhou M, Venkata PP, Viswanadhapalli S, Palacios B, Alejo S, Chen Y, He Y, Pratap UP, Liu J, Zou Y, Lai Z, Suzuki T, Brenner AJ, Tekmal RR, Vadlamudi RK, Sareddy GR.
    Breast Cancer Res Treat; 2021 Jan 10; 185(2):343-357. PubMed ID: 33057995
    [Abstract] [Full Text] [Related]

  • 6. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells.
    Chu J, Li Y, Fan X, Ma J, Li J, Lu G, Zhang Y, Huang Y, Li W, Huang X, Fu Z, Yin Y, Yuan H.
    Cell Physiol Biochem; 2018 Jan 10; 48(2):593-604. PubMed ID: 30021199
    [Abstract] [Full Text] [Related]

  • 7. Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide.
    Cámara-Sánchez P, Díaz-Riascos ZV, García-Aranda N, Gener P, Seras-Franzoso J, Giani-Alonso M, Royo M, Vázquez E, Schwartz S, Abasolo I.
    Int J Mol Sci; 2022 Oct 04; 23(19):. PubMed ID: 36233074
    [Abstract] [Full Text] [Related]

  • 8. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.
    Teslow EA, Mitrea C, Bao B, Mohammad RM, Polin LA, Dyson G, Purrington KS, Bollig-Fischer A.
    Mol Oncol; 2019 Apr 04; 13(4):894-908. PubMed ID: 30636104
    [Abstract] [Full Text] [Related]

  • 9. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP, Lim G, Li Y, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, Sun D, Zhang T.
    Cancer Lett; 2017 May 28; 394():52-64. PubMed ID: 28254410
    [Abstract] [Full Text] [Related]

  • 10. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
    Chen F, Luo N, Hu Y, Li X, Zhang K.
    Cell Physiol Biochem; 2018 May 28; 47(5):2147-2158. PubMed ID: 29975921
    [Abstract] [Full Text] [Related]

  • 11. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
    Al-Marsoummi S, Vomhof-DeKrey E, Basson MD.
    Cell Physiol Biochem; 2019 May 28; 53(6):999-1014. PubMed ID: 31838790
    [Abstract] [Full Text] [Related]

  • 12. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L, Nuncia-Cantarero M, Morcillo-Garcia S, Nieto-Jimenez C, Burgos M, Corrales-Sanchez V, Perez-Peña J, Győrffy B, Ocaña A, Galán-Moya EM.
    Cell Oncol (Dordr); 2020 Jun 28; 43(3):431-444. PubMed ID: 32166583
    [Abstract] [Full Text] [Related]

  • 13. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
    Zhou L, Wang D, Sheng D, Xu J, Chen W, Qin Y, Du R, Yang X, He X, Xie N, Liu S, Zhang L.
    Theranostics; 2020 Jun 28; 10(5):2405-2421. PubMed ID: 32104513
    [Abstract] [Full Text] [Related]

  • 14. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
    Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, Li L, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Liu S, Xie Y, Gadde S, Li X, Wang L.
    Cell Death Dis; 2018 Jul 26; 9(8):815. PubMed ID: 30050079
    [Abstract] [Full Text] [Related]

  • 15. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
    Li Y, Xiao Y, Lin HP, Reichel D, Bae Y, Lee EY, Jiang Y, Huang X, Yang C, Wang Z.
    Biomaterials; 2019 Jan 26; 188():160-172. PubMed ID: 30352320
    [Abstract] [Full Text] [Related]

  • 16. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
    Wu D, Jia H, Zhang Z, Li S.
    Bioorg Chem; 2021 Apr 26; 109():104722. PubMed ID: 33618253
    [Abstract] [Full Text] [Related]

  • 17. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
    Doherty MR, Parvani JG, Tamagno I, Junk DJ, Bryson BL, Cheon HJ, Stark GR, Jackson MW.
    Breast Cancer Res; 2019 Apr 29; 21(1):54. PubMed ID: 31036052
    [Abstract] [Full Text] [Related]

  • 18. Elevated expression of the rhythm gene NFIL3 promotes the progression of TNBC by activating NF-κB signaling through suppression of NFKBIA transcription.
    Yang W, Li J, Zhang M, Yu H, Zhuang Y, Zhao L, Ren L, Gong J, Bi H, Zeng L, Xue Y, Yang J, Zhao Y, Wang S, Gao S, Fu Z, Li D, Zhang J, Wang T, Shan M, Tang B, Li X.
    J Exp Clin Cancer Res; 2022 Feb 18; 41(1):67. PubMed ID: 35180863
    [Abstract] [Full Text] [Related]

  • 19. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M, Li AQ, Zhou SL, Lv H, Wei P, Yang WT.
    J Exp Clin Cancer Res; 2020 May 24; 39(1):92. PubMed ID: 32448269
    [Abstract] [Full Text] [Related]

  • 20. LRPPRC promotes glycolysis by stabilising LDHA mRNA and its knockdown plus glutamine inhibitor induces synthetic lethality via m6 A modification in triple-negative breast cancer.
    Yu Y, Deng H, Wang W, Xiao S, Zheng R, Lv L, Wang H, Chen J, Zhang B.
    Clin Transl Med; 2024 Feb 24; 14(2):e1583. PubMed ID: 38372449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.